5 results
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients (no prior exposure to factor products or any blood products) of less than 6 years of age.
Our proposed randomized controlled trial is the first making this head-to-head comparison in a *real life* primary care setting in the Netherlands. The primary research question is: does a 12-week combination therapy of open label varenicline and…
Drug craving and impulsivity will be assessed with questionnaires, fMRI/EEG using cue-reactivity and impulsivity paradigms. Relapse will be assessed by checking urine samples every week.
This study aims to evaluate IDRX-42 administered to participants with metastatic and/or surgically unresectable GIST.
To investigate the reliability and feasibility of PK-guided prophylactic dosing of factor concentrates in hemophilia A and B patients (predictive performance).